Redeye acknowledges a milestone for Idogen with the successful transfer of manufacturing technology of its cell therapy to Radboud University, which is yet another vital step towards clinic. Next step in the process will be to achieve manufacturing in accordance to GMP-standards. From a stock market point of view, we argue that the initiation of a Phase I/II trial with IDO-8 (wich we expect in Q2 2021) will be a true inflection point, as many investors are cautious to invest in the preclinical stage.